Real-World Data Show Leqvio's Effectiveness in Reducing LDL-C in Patients With ASCVD

Results from the V-INITIATE trial showed a substantial 60% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline to day 330 in the inclisiran first group compared with a mere 7% reduction in the usual care group.

Related Keywords

,David Soergel ,Michael Koren ,Jacksonville Center ,Journal Of The American College Cardiology ,Clinical Research ,European Union ,Novartis ,Annual Scientific Session ,American College ,Leqvio ,Inclisiran ,Ascvd ,American College Of Cardiology ,